Arctic Bioscience AS (OSL:ABS) Short-Term Debt: kr35.98 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSL:ABS Arctic Bioscience AS OSL:ABS
53 GF Score
Price kr3.06
GF Value kr10.90
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Arctic Bioscience AS Short-Term Debt?

Arctic Bioscience AS OSL:ABS -2.86% 53 Short-Term Debt is kr35.98 Mil as of Dec. 2025. GuruFocus rates OSL:ABS with a GF Score™ of 53/100 and a GF Value™ of kr10.90 (Possible Value Trap). The stock has 6 warning signs investors should review.

Arctic Bioscience AS's Short-Term Debt for the quarter that ended in Dec. 2025 was kr35.98 Mil.

Arctic Bioscience AS's quarterly Short-Term Debt declined from Dec. 2024 (kr31.39 Mil) to Jun. 2025 (kr26.96 Mil) but then increased from Jun. 2025 (kr26.96 Mil) to Dec. 2025 (kr35.98 Mil).

Arctic Bioscience AS's annual Short-Term Debt increased from Dec. 2023 (kr3.53 Mil) to Dec. 2024 (kr31.39 Mil) and increased from Dec. 2024 (kr31.39 Mil) to Dec. 2025 (kr35.98 Mil).

Arctic Bioscience AS Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Arctic Bioscience AS Short-Term Debt Related Terms

Arctic Bioscience AS Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Arctic Bioscience AS's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Arctic Bioscience AS Short-Term Debt Chart

Arctic Bioscience AS Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Short-Term Debt
Get a 7-Day Free Trial 1.27 1.10 3.53 31.39 35.98

Arctic Bioscience AS Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.53 0.00 31.39 26.96 35.98
OSL:ABS
53GF Score
Arctic Bioscience AS OSL:ABS
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of kr35.98 Mil mean?
Arctic Bioscience AS (OSL:ABS) has a Short-Term Debt of kr35.98 Mil as of Dec. 2025.
Is Arctic Bioscience AS's Short-Term Debt too high?
Arctic Bioscience AS's current Short-Term Debt is kr35.98 Mil. Overall, Arctic Bioscience AS has a GF Score™ of 53/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Arctic Bioscience AS's Short-Term Debt compare to VRTX and REGN?
Arctic Bioscience AS's Short-Term Debt of kr35.98 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Biotechnology company?
A good Short-Term Debt depends on the Biotechnology industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Arctic Bioscience AS's current Short-Term Debt is kr35.98 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arctic Bioscience AS stock overvalued right now?
Based on GuruFocus' analysis, Arctic Bioscience AS (OSL:ABS) is currently considered Possible Value Trap. The stock's GF Value™ is kr10.90, compared to a current price of kr3.06 — trading 71.9% below its estimated fair value. The current Short-Term Debt is kr35.98 Mil. Arctic Bioscience AS's overall GF Score™ is 53/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Arctic Bioscience AS (OSL:ABS), the current Short-Term Debt is kr35.98 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Arctic Bioscience AS (OSL:ABS) Overvalued in 2026?

Based on GuruFocus' analysis, Arctic Bioscience AS stock appears to be undervalued. The current stock price of kr3.06 is trading 71.9% below its estimated GF Value™ of kr10.90. GuruFocus considers Arctic Bioscience AS to be Possible Value Trap.

Key valuation signals for OSL:ABS:

  • Short-Term Debt: kr35.98 Mil
  • GF Value™: kr10.90 vs. price of kr3.06 (71.9% below fair value)
  • GF Score™: 53/100 with 6 warning signs

No single metric tells the full story. See the OSL:ABS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Arctic Bioscience AS Business Description

Other Exchanges 9TD:Germany
Address Industrivegen 42, Orsta, NOR, 6155
Arctic Bioscience AS is a clinical-stage biotechnology company working to develop drug candidates within the areas of autoimmune and inflammatory diseases. It is developing pharmaceutical and commercializing nutraceutical products based on bioactive marine compounds, including lipids essential to maintaining cell membranes. The company's proprietary extraction technology is used to extract membrane fats from marine raw materials, such as herring roe and algae. Geographically, the company operates in Norway, the Americas, Europe, and APAC, with the majority of the revenue derived from the Americas.
53GF Score

Get the complete analysis for OSL:ABS

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr3.06
Price
kr10.90
GF Value